• Strategic Assay Optimization with JNJ-26854165 (Serdemetan)

  2026-04-21

  Explore how JNJ-26854165 (Serdemetan) enables precision assay design in cancer research. This article uniquely bridges advanced in vitro methodology with practical workflow decisions for anti-proliferative and apoptosis-focused studies.

• KPT-330 (Selinexor): Optimizing CRM1 Inhibition for Cancer R

  2026-04-20

  KPT-330 (Selinexor) enables precise inhibition of nuclear export in cancer models, driving apoptosis and tumor growth suppression. This article details use-case strategies, protocol enhancements, and troubleshooting tips that empower researchers to maximize the impact of CRM1 inhibition in translational oncology.

• JNK-IN-7: Precision Tools for JNK Pathway and Apoptosis Rese

  2026-04-20

  This article provides translational researchers with a mechanistic and strategic exploration of JNK-IN-7, a selective JNK inhibitor, emphasizing its role in dissecting MAPK signaling, apoptosis, and innate immune modulation. Drawing on recent literature—including the distinct apoptotic pathways in bovine mastitis—this piece delivers actionable guidance, contrasts JNK-IN-7 with alternative tools, and highlights the unique value of APExBIO’s compound for advanced cellular signaling studies.

• LLY-507: Precision SMYD2 Inhibitor for Cancer & Fibrosis Ass

  2026-04-19

  LLY-507 empowers researchers with exceptional selectivity and nanomolar potency for dissecting SMYD2-driven pathways in cancer and fibrosis. Its proven performance in both oncology and renal disease models sets a new benchmark for epigenetic inhibitor workflows.

• Structural Basis for PSS2 Regulation of SREBP Pathways in Ce

  2026-04-18

  This study elucidates the molecular mechanism by which human phosphatidylserine synthase 2 (PSS2) selectively uses phosphatidylethanolamine (PE) as a substrate and exerts a distinct, inhibitory effect on SREBP-1/2 cleavage. The findings, supported by cryo-EM structure and lipidomics analysis, reveal functional divergence between homologous PSS1 and PSS2, providing insight into phospholipid regulation and cholesterol homeostasis.

• Angiotensin III (human, mouse): Advanced Receptor Profiling

  2026-04-17

  Explore the multifaceted role of Angiotensin III (human, mouse) in receptor signaling and its emerging links to viral pathogenesis. This article uniquely combines peptide structure, mechanistic depth, and translational implications for cardiovascular and infectious disease research.

• Ibuprofen in Cancer Research: Protocols, Performance & Pitfa

  2026-04-16

  APExBIO's Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) stands out as an anti-proliferative agent for colon cancer research, enabling precise apoptosis and cell cycle assays. This guide delivers evidence-based workflows, comparative insights, and troubleshooting strategies for maximizing experimental reproducibility.

• Mubritinib–HSA Binding: Molecular Mechanisms and Implication

  2026-04-15

  This article dissects recent findings on the interaction between the mitochondrial electron transport chain inhibitor mubritinib and human serum albumin (HSA). The study reveals moderate binding affinity, protein structural perturbation, and functional alterations, providing foundational insight into drug pharmacokinetics and delivery relevant to cancer research.

• Cell Death Mechanisms in Liver Disease: Clinical Relevance a

  2026-04-14

  This review synthesizes current understanding of hepatocellular death as a central driver in liver disease progression, detailing how distinct modes of cell death—apoptosis, necrosis, and necroptosis—impact inflammation, fibrosis, and carcinogenesis. By connecting molecular insights to clinical applications, the paper highlights cell death pathways as potential therapeutic targets with broad translational significance.

• Nelfinavir Mesylate: Bridging HIV Inhibition & Ferroptosis

  2026-04-13

  This thought-leadership article examines Nelfinavir Mesylate’s dual role as a gold-standard HIV-1 protease inhibitor and as a strategic probe for modulating ferroptosis via the DDI2-NFE2L1-ubiquitin-proteasome axis. Integrating mechanistic insights, rigorous protocol guidance, and translational foresight, it equips researchers to unlock new frontiers in HIV infection research and regulated cell death modeling. This piece advances discussion beyond standard product pages, weaving evidence-based recommendations with strategic analysis for next-generation translational research.

• Cy7 NHS Ester: Practical Guidance for NIR Protein Labeling

  2026-04-13

  Cy7 NHS ester enables efficient, high-sensitivity labeling of proteins and peptides for near-infrared (NIR) fluorescent imaging, addressing solubility and quenching challenges common with traditional dyes. It is best suited for applications requiring aqueous labeling conditions and is not recommended where long-term dye solution storage is required.

• GI 254023X: Reliable ADAM10 Inhibitor for Cell-Based Assays

  2026-04-12

  This article delivers an evidence-driven, scenario-focused analysis of GI 254023X (SKU A4436), a highly selective ADAM10 inhibitor from APExBIO. Integrating real-world laboratory challenges—from protocol optimization to data interpretation—the discussion underscores GI 254023X’s nanomolar potency, workflow compatibility, and reliability for cell viability, proliferation, and cytotoxicity assays.

• Heparin Sodium in Multiscale Coagulation Modeling: From Mech

  2026-04-12

  Explore how Heparin sodium, a leading glycosaminoglycan anticoagulant, is redefining advanced thrombosis research through integration with nanotechnology and emerging bio-nanovesicle strategies. Discover rigorous protocols, technical insights, and the impact of recent molecular findings on practical assay design.

• Cytarabine (AraC): Precision Apoptosis Induction in Leukemia

  2026-04-11

  Cytarabine (AraC) sets the standard as an apoptosis inducer in leukemia research, offering mechanistic clarity and reproducible outcomes. This article delivers actionable protocol insights, troubleshooting strategies, and a translational perspective, empowering researchers to leverage APExBIO’s Cytarabine for maximum experimental rigor.

• PD 0332991 (Palbociclib) HCl: Optimizing CDK4/6 Inhibition W

  2026-04-11

  PD 0332991 (Palbociclib) HCl delivers robust, selective cell cycle arrest in Rb-positive tumor models, enabling highly reproducible antiproliferative studies. This guide distills recent mechanistic breakthroughs and workflow refinements, ensuring researchers stay at the forefront of CDK4/6 pathway interrogation.

16734 records 1/1116 page Next 12345 下5页 Last page